Inactive Instrument

GOLD SWAP Share Price OTC Bulletin Board

GDSW

US38074W1009

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

10/07	Top Midday Decliners	MT
10/07	Silo Pharma Launches Private Placement to Raise Up to $11.7 Million	MT

Analysts' recommendations: GOLD SWAP

19/24/19	Top Midday Decliners	MT
28/23/28	Laidlaw Initiates Silo Pharma With Buy Rating, Price Target is $10	MT

More recommendations

Managers and Directors: GOLD SWAP

Manager	Title	Age	Since
Eric Weisblum CEO	Chief Executive Officer	57	27/11/2015
Daniel Ryweck DFI	Director of Finance/CFO	62	27/09/2022
James Kuo CTO	Chief Tech/Sci/R&D Officer	60	01/09/2022

Director	Title	Age	Since
Eric Weisblum CHM	Chairman	57	27/11/2015
Wayne Linsley BRD	Director/Board Member	69	16/01/2020
Kevin Muñoz BRD	Director/Board Member	47	01/10/2020

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-1.07%	+0.38%	+2.06%	+5.66%	5.03TCr
REVOLUTION MEDICINES, INC.	-2.85%	-5.58%	+373.90%	+572.09%	3.92TCr
IQVIA HOLDINGS INC.	+1.78%	+3.29%	+33.49%	-4.80%	3.45TCr
BEONE MEDICINES AG	+1.98%	+5.15%	+17.69%	+61.68%	3.46TCr
CELLTRION, INC.	+0.06%	-0.57%	+3.35%	+27.42%	2.7TCr
ASCENDIS PHARMA A/S	-3.27%	-6.27%	-	-	1.67TCr
MEDPACE HOLDINGS, INC.	+1.64%	+1.11%	+72.02%	+121.18%	1.51TCr
EUROFINS SCIENTIFIC SE	+0.29%	+3.64%	+15.30%	+17.80%	1.39TCr
ICON PUBLIC LIMITED COMPANY	-1.21%	+2.74%	+16.77%	-30.96%	1.32TCr
Average	+0.01%	+0.81%	+66.82%	+96.26%	2.72TCr
Weighted average by Cap.	+0.13%	+0.70%	+79.63%	+118.91%

See all sector performances

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Companyâ€™s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Companyâ€™s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimerâ€™s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimerâ€™s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Employees

Sector

Biotechnology & Medical Research

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	51.84L 45.3L 41.92L 38.47L 72.79L 50Cr 74.1L 5Cr 1.96Cr 24Cr 1.95Cr 1.9Cr 84Cr	P/E 2024	-0.75x	P/E 2025	-0.67x
Enterprise Value	-16.75L -14.64L -13.55L -12.43L -23.52L -16Cr -23.95L -1.61Cr -63.32L -7.87Cr -62.89L -61.52L -27Cr	EV / Sales 2024	-42.8x	EV / Sales 2025	-32.3x
Free-Float	73.7%	Yield 2024 *	-	Yield 2025	-

10/07	Top Midday Decliners	MT
10/07	Silo Pharma Launches Private Placement to Raise Up to $11.7 Million	MT
09/07	Silo Pharma, Inc. announced that it has received $4.000015 million in funding	CI
30/06	Silo Pharma Advances SPC-15 PTSD Therapeutic With Drug-Device Robustness Study Ahead Of Planned FDA Type C Meeting Request	CI
23/06	Silo Pharma, Inc. Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-In-Human Clinical Trial	CI
23/06	Silo Pharma Says SPC-15 PTSD Nasal Spray Remains Stable for 9 Months	MT
18/06	Silo Pharma Says it Regained Compliance With Nasdaq's Minimum Bid Price Requirement	MT
04/06	Silo Pharma Shares Drop Following Implementation of 1-for-15 Reverse Stock Split	MT
14/05	Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on February 23, 2026.	CI
14/05	Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury	CI
29/04	Silo Pharma's PTSD program advances as FDA fast-tracks psychedelic therapies for PTSD	RE
29/04	Silo Pharma, Inc. Announces Its PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD	CI

14/07	Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform	AQ
10/07	Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules	AQ
07/07	Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program	AQ
30/06	Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request	AQ
23/06	Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial	AQ

	2024	2025
Net sales	72.1T 63.01T 58.31T 53.52T 1L 69.46L 1L 7L 3L 33.88L 3L 3L 1.17Cr	72.1T 63.01T 58.31T 53.52T 1L 69.46L 1L 7L 3L 33.88L 3L 3L 1.17Cr
Net income	-43.93L -38.39L -35.52L -32.61L -61.68L -42Cr -62.79L -4.23Cr -1.66Cr -21Cr -1.65Cr -1.61Cr -71Cr	-42.28L -36.95L -34.19L -31.38L -59.36L -41Cr -60.43L -4.07Cr -1.6Cr -20Cr -1.59Cr -1.55Cr -69Cr
Net Debt	-70.81L -61.88L -57.26L -52.55L -99.42L -68Cr -1.01Cr -6.82Cr -2.68Cr -33Cr -2.66Cr -2.6Cr -114.97Cr	-68.59L -59.94L -55.46L -50.91L -96.31L -66Cr -98.04L -6.61Cr -2.59Cr -32Cr -2.57Cr -2.52Cr -111.37Cr

GOLD SWAP Share Price OTC Bulletin Board

Stocks

GDSW

US38074W1009

Biotechnology & Medical Research

Valuation: GOLD SWAP

Latest news : GOLD SWAP

Analysts' recommendations: GOLD SWAP

Press Releases: GOLD SWAP

Managers and Directors: GOLD SWAP

Other Biotechnology & Medical Research

Financials

Company Profile